MEIHUA BIO、MeiHua Group(SH:600873) China Post Securities·2025-06-16 05:13Investment Rating - The report maintains a "Buy" investment rating for the company, indicating a positive outlook for its stock performance relative to the market [6][7]. Core Insights - The company reported a revenue of 250.69 billion yuan for 2024, a decrease of 9.69% year-on-year, and a net profit attributable to shareholders of 27.40 billion yuan, down 13.85% year-on-year. However, the first quarter of 2025 showed a net profit increase of 35.52% year-on-year, driven by higher sales volumes of key products [7]. - The company is expanding its production capacity and enhancing its international presence, with significant investments in R&D amounting to 733 million yuan, focusing on basic research and new technologies [7]. - The projected net profits for 2025, 2026, and 2027 are 31.44 billion yuan, 33.67 billion yuan, and 37.45 billion yuan, respectively, with corresponding EPS of 1.10, 1.18, and 1.31 yuan [7][8]. Company Overview - The latest closing price of the company's stock is 10.68 yuan, with a total market capitalization of 305 billion yuan. The company has a debt-to-asset ratio of 38.8% and a price-to-earnings ratio of 11.36 [3][4]. Financial Forecasts - The company is expected to see a revenue increase in the coming years, with projected revenues of 272 billion yuan in 2025, 302 billion yuan in 2026, and 321 billion yuan in 2027, reflecting growth rates of 8.32%, 11.16%, and 6.45%, respectively [8][9]. - The EBITDA is forecasted to grow from 46.92 billion yuan in 2024 to 58.90 billion yuan in 2027, indicating improving operational efficiency [8].